Tilray Inc's stock has seen a slight decline this week amidst recent company developments.
This week, Tilray Inc (TLRY.TO) experienced a modest drop, closing at C$6.11 on Friday, down 0.49% for the day and 1.61% for the week. The stock has faced significant challenges this year, with a year-to-date decline of 54.23%. Despite this downturn, the company has made strides in expanding its product offerings and reporting strong revenue figures.
Advertisement
Tilray Inc
TLRY.TO
TLRY.TO
Tilray Inc
WealthAwesomeAdvertisement
Market cap
$839.01M
52W high
$32.30
52W low
$5.19
1W change
-2.84%
Beta
1.92
Analyst Price Targets
Based on analyst covering TLRY
Wall Street analysts forecast TLRY stock price to rise 23.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.59
+23.2% Upside
Current Price
C$6.16
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TLRY's historical volatility
30-Day Vol
47.8%
Annualized
90-Day Vol
53.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$5.15
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.80 | C$4.92 – C$6.84 |
| 60 trading days | C$5.47 | C$4.33 – C$6.90 |
| 90 trading days | C$5.15 | C$3.87 – C$6.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep an eye on Tilray's recent developments, including its expansion into new markets and upcoming financial results. However, the stock's significant decline this year raises questions about the company's long-term prospects.
Tilray's stock has declined 54.23% year-to-date.
Despite a strong Q2 performance, the stock's significant drop raises concerns about its future growth and market conditions.
Bull case
The upcoming release of Tilray's Q4 and fiscal year 2026 financial results may provide positive insights into the company's performance, especially after a record Q2 revenue of $218 million. Additionally, launching medical cannabis products in Panama could boost its market presence and drive growth.
Bear case
The stock has struggled significantly this year, with a year-to-date drop of over 54%. The negative profit margin and high beta of 1.90 indicate volatility, which may concern risk-averse investors. Furthermore, the stock is trading well below its 50-day and 200-day moving averages, suggesting ongoing weakness.
Recent Price Action
Advertisement
Tilray Inc's stock closed at C$6.11 on Friday, marking a 0.49% decline for the day. Over the past week, the stock has dropped 1.61%, continuing a troubling trend with a year-to-date decrease of 54.23%. With a 52-week range between C$5.98 and C$32.30, the stock is currently at the lower end of this spectrum.
Company Developments
Recent headlines surrounding Tilray include its upcoming announcement of Q4 and fiscal year 2026 financial results scheduled for July 28, 2026. The company has also expanded its medical cannabis offerings into Panama, enhancing access for patients in Latin America. Additionally, Tilray reported a record net revenue of $218 million for Q2 of fiscal 2026, reaffirming its full-year adjusted EBITDA guidance.
Technical Picture
From a technical perspective, Tilray's stock is trading below both its 50-day moving average of C$6.99 and its 200-day moving average of C$7.89, indicating a bearish trend. The stock's beta of 1.90 suggests higher volatility compared to the overall market. The current trading volume stands at 364,385 shares, which is below the 20-day average volume of 425,531 shares, reflecting reduced trading interest.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
